X

Leveraging academic medicine into innovative therapies through partnerships

Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development

Clinical Trials

Vamorolone is in clinical testing for DMD, with 46 patients enrolled in VBP15-LTE (NCT03038399) and recruitment of 120 new patients initiated for VBP15-004 (NCT03439670).
Learn more >

About vamorolone

Vamorolone Phase 2a study complete.
Phase 2b study initiated.

Learn More

Research

microRNAs shown to define dystrophin levels in patient muscle (Fiorillo et al. 2015) – IP licensed to ReveraGen.

Learn More

News

Pratteln, Switzerland, and Rockville, MD, USA, September 22, 2020

Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data More >

Learn More